| 報告時間：2026-09-23 | |
| 報告地點：大四教室 | |
| 指導老師：陳彥伯 | |
| 學生：郭宇安 | |
| 摘要 | |
| High-fat and high-sugar diets in modern lifestyles have driven a surge in diabetes. According to the 2025 Diabetes in Special Populations in Taiwan, the prevalence rate reached 10.707% in 2020, with Type 2 Diabetes Mellitus (T2DM) accounting for 99.5% of cases. Chronic hyperglycemia elevates metabolic pressure on glomeruli and renal tubules, ultimately leading to Diabetic Kidney Disease (DKD). Managing DKD requires first addressing T2DM, which is characterized by insulin receptor dysfunction and insulin resistance. Although conventional medications like DPP-4 inhibitors help control blood glucose, they carry risks of gastrointestinal side effects and hypoglycemia. Enhancing glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and suppresses glucagon, offering a promising therapeutic strategy. However, due to the high cost of GLP-1 receptor agonists (GLP-1RAs), current research has shifted toward natural agents that stimulate endogenous GLP-1 secretion. The high-dose bacterial lysate (HL) of Bifidobacterium breve i1088 has demonstrated a strong capacity to stimulate GLP-1 secretion in both in vitro and in vivo models, effectively managing blood glucose and lipids with superior efficacy compared to live bacteria. Furthermore, HL exhibits anti-inflammatory properties by reducing IL-6 and IL-1β levels in T2DM mice, with 5-hydroxyindoleacetic acid (5-HIAA) identified as the key active metabolite. While established studies show that GLP-1RAs protect the kidney by phosphorylating sodium-hydrogen exchanger 3 (NHE3) to reduce sodium reabsorption and lower renal stress, enhanced endogenous GLP-1 secretion is expected to yield similar receptor activation. Therefore, probiotics and postbiotics that boost GLP-1 secretion hold substantial potential to ameliorate T2DM while simultaneously reducing renal metabolic pressure and mitigating DKD.
|